Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Challenges and Strategies to Combat Resistance Mechanisms in Thyroid Cancer Therapeutics.

Thyroid : official journal of the American Thyroid Association - 1 Jun 2023

Gild Matti L, Bullock Martyn, Tsang Venessa, Clifton-Bligh Roderick J, Robinson Bruce G, Wirth Lori J

Abstract excerpt

Background: BRAFV600E and N/H/K RAS mutations and oncogenic kinase fusions involving neurotrophin tyrosine receptor kinase (NTRK), RET, anaplastic lymphoma kinase (ALK), and ROS1 have been identified as actionable targets in thyroid cancer. These driver alterations lead to oncogene addiction, which has been successfully exploited through tyrosine kinase inhibitors. Acquired resistance may develop following an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Neoplasms
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protein Kinase Inhibitors

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins

Share to Receptor Protein-Tyrosine Kinases

Share to Thyroid Neoplasms

Source

Identifiers

PMID: 36924302
DOI: 10.1089/thy.2022.0704

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Challenges and Strategies to Combat Resistance Mechanisms in Thyroid Cancer Therapeutics.PMID 36924302Read ↗

Mechanisms of resistance to RET-directed therapiesSemantic proximity Read ↗

Clinical and Translational Challenges in Thyroid Cancer.Semantic proximity Read ↗

Targeted therapy in thyroid cancer: molecular alterations and clinical management.Semantic proximity Read ↗

This is Your Thyroid on Drugs: Targetable Mutations and Fusions in Thyroid Carcinoma.Semantic proximity Read ↗

This is Your Thyroid on Drugs: Targetable Mutations and Fusions in Thyroid Carcinoma.Semantic proximity Read ↗

The Role of the Kinase Inhibitors in Thyroid CancersSemantic proximity Read ↗

Targeting RET alterations in cancer: Recent progress and future directions.Semantic proximity Read ↗

MANAGEMENT OF ENDOCRINE DISEASE: Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectivesSemantic proximity Read ↗

Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectivesSemantic proximity Read ↗

Promising Therapeutic Targets for Recurrent/Metastatic Anaplastic Thyroid Cancer.Semantic proximity Read ↗

KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid CancerSemantic proximity Read ↗

Combination of Selpercatinib and Trametinib Overcomes Resistance to RET Inhibitors in RET-Mutant Medullary Thyroid Carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.